Therapeutic effects of add-on low-dose dextromethorphan plus valproic acid in bipolar disorder

European Neuropsychopharmacology

Volumn 24, Issue 11, 2014, Pages 1753-1759

  Chen, Shiou Lan ^a   Lee, Sheng Yu ^f   Chang, Yun Hsuan ^b,c,d   Chen, Po See ^b,c   Lee, I Hui ^a,b   Wang, Tzu Yun ^b,c   Chen, Kao Ching ^b,c   Yang, Yen Kuang ^b,c,d   Hong, Jau Shyong ^g   Lu, Ru Band ^b,c,d,e  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^d NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^e NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^f Department of Nursing   (Taiwan)

^g NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

BDNF; Bipolar disorder; Cytokine; HDRS; YMRS

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; CYTOKINE; DEXTROMETHORPHAN; FLUOXETINE; INTERLEUKIN 8; LORAZEPAM; PLACEBO; RISPERIDONE; TUMOR NECROSIS FACTOR ALPHA; VALPROIC ACID; BIOLOGICAL MARKER; NEUROPROTECTIVE AGENT; TRANQUILIZER;

ADD ON THERAPY; ADULT; AGED; ARTICLE; BIPOLAR DISORDER; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRAPYRAMIDAL SYNDROME; FEMALE; FOLLOW UP; HAMILTON SCALE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SUICIDE ATTEMPT; THERAPY EFFECT; YOUNG MANIA RATING SCALE; BLOOD; DRUG COMBINATION; PSYCHOLOGICAL RATING SCALE; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; ANTIMANIC AGENTS; BIOLOGICAL MARKERS; BIPOLAR DISORDER; BRAIN-DERIVED NEUROTROPHIC FACTOR; CYTOKINES; DEXTROMETHORPHAN; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; NEUROPROTECTIVE AGENTS; PSYCHIATRIC STATUS RATING SCALES; TREATMENT OUTCOME; VALPROIC ACID; YOUNG ADULT;

EID: 84918551548     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2014.09.001     Document Type: Article

References (34)

1. Alderson R.F., Alterman A.L., Barde Y.A., Lindsay R.M. Brain-derived neurotrophic factor increases survival and differentiated functions of rat septal cholinergic neurons in culture. Neuron 1990, 5(3):297-306.
2. Benazzi F., Akiskal H. The duration of hypomania in bipolar-II disorder in private practice: methodology and validation. J. Affect. Disord. 2006, 96(3):189-196.
3. Beyer J.L., Krishnan K.R. Volumetric brain imaging findings in mood disorders. Bipolar Disord. 2002, 4(2):89-104.
4. Boerlin H.L., Gitlin M.J., Zoellner L.A., Hammen C.L. Bipolar depression and antidepressant-induced mania: a naturalistic study. J. Clin. Psychiatry 1998, 59(7):374-379.
5. Chen S.L., Lee S.Y., Chang Y.H., Chen S.H., Chu C.H., Tzeng N.S., Lee I.H., Chen P.S., Yeh T.L., Huang S.Y., Yang Y.K., Lu R.B., Hong J.S. Inflammation in patients with schizophrenia: the therapeutic benefits of risperidone plus add-on dextromethorphan. J. Neuroimmune Pharmacol. 2012, 7(3):656-664.
6. Chen S.L., Lee S.Y., Tao P.L., Chang Y.H., Chen S.H., Chu C.H., Chen P.S., Lee I.H., Yeh T.L., Yang Y.K., Hong J.S., Lu R.B. Dextromethorphan attenuated inflammation and combined opioid use in humans undergoing methadone maintenance treatment. J. Neuroimmune Pharmacol. 2012.
7. Church J., Sawyer D., McLarnon J.G. Interactions of dextromethorphan with the N-methyl-d-aspartate receptor-channel complex: single channel recordings. Brain Res. 1994, 666(2):189-194.
8. Cirulli F., Francia N., Branchi I., Antonucci M.T., Aloe L., Suomi S.J., Alleva E. Changes in plasma levels of BDNF and NGF reveal a gender-selective vulnerability to early adversity in rhesus macaques. Psychoneuroendocrinology 2009, 34(2):172-180.
9. Dunner D. Diagnostic revision for DSM-IV. Mania, Clinical and Research Perspectives 1998, 3-10. American Psychiatric Press, Washington, DC. P. Goodnick (Ed.).
10. Endicott J., Spitzer R.L. A diagnostic interview: the schedule for affective disorders and schizophrenia. Arch. Gen. Psychiatry 1978, 35(7):837-844.
11. Goldstein B.I., Kemp D.E., Soczynska J.K., McIntyre R.S. Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature. J. Clin. Psychiatry 2009, 70(8):1078-1090.
12. Grande I., Fries G.R., Kunz M., Kapczinski F. The role of BDNF as a mediator of neuroplasticity in bipolar disorder. Psychiatry Investig. 2010, 7(4):243-250.
13. Howland R.H. Induction of mania with serotonin reuptake inhibitors. J. Clin. Psychopharmacol. 1996, 16(6):425-427.
14. Huang S.Y., Lin W.W., Ko H.C., Lee J.F., Wang T.J., Chou Y.H., Yin S.J., Lu R.B. Possible interaction of alcohol dehydrogenase and aldehyde dehydrogenase genes with the dopamine D2 receptor gene in anxiety-depressive alcohol dependence. Alcohol Clin. Exp. Res. 2004, 28(3):374-384.
15. Hyman C., Hofer M., Barde Y.A., Juhasz M., Yancopoulos G.D., Squinto S.P., Lindsay R.M. BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature 1991, 350(6315):230-232.
16. Karege F., Schwald M., Cisse M. Postnatal developmental profile of brain-derived neurotrophic factor in rat brain and platelets. Neurosci. Lett. 2002, 328(3):261-264.
17. Kempton M.J., Geddes J.R., Ettinger U., Williams S.C., Grasby P.M. Meta-analysis, database, and meta-regression of 98 structural imaging studies in bipolar disorder. Arch. Gen. Psychiatry 2008, 65(9):1017-1032.
18. Kunz M., Cereser K.M., Goi P.D., Fries G.R., Teixeira A.L., Fernandes B.S., Belmonte-de-Abreu P.S., Kauer-Sant'anna M., Kapczinski F., Gama C.S. Serum levels of IL-6, IL-10 and TNF-alpha in patients with bipolar disorder and schizophrenia: differences in pro- and anti-inflammatory balance. Rev. Bras. Psiquiatr. 2011.
19. Laske C., Stransky E., Leyhe T., Eschweiler G.W., Wittorf A., Richartz E., Bartels M., Buchkremer G., Schott K. Stage-dependent BDNF serum concentrations in Alzheimer's disease. J. Neural Transm. 2006, 113(9):1217-1224.
20. Li G., Cui G., Tzeng N.S., Wei S.J., Wang T., Block M.L., Hong J.S. Femtomolar concentrations of dextromethorphan protect mesencephalic dopaminergic neurons from inflammatory damage. FASEB J. 2005, 19(6):489-496.
21. Liu Y., Qin L., Li G., Zhang W., An L., Liu B., Hong J.S. Dextromethorphan protects dopaminergic neurons against inflammation-mediated degeneration through inhibition of microglial activation. J. Pharmacol. Exp. Ther. 2003, 305(1):212-218.
22. MacQueen G.M., Young L.T., Joffe R.T. A review of psychosocial outcome in patients with bipolar disorder. Acta Psychiatr. Scand. 2001, 103(3):163-170.
23. Monteleone P., Serritella C., Martiadis V., Maj M. Decreased levels of serum brain-derived neurotrophic factor in both depressed and euthymic patients with unipolar depression and in euthymic patients with bipolar I and II disorders. Bipolar Disord. 2008, 10(1):95-100.
24. Pan W., Banks W.A., Fasold M.B., Bluth J., Kastin A.J. Transport of brain-derived neurotrophic factor across the blood-brain barrier. Neuropharmacology 1998, 37(12):1553-1561.
25. Pan W., Kastin A.J. Penetration of neurotrophins and cytokines across the blood-brain/blood-spinal cord barrier. Adv. Drug Deliv. Rev. 1999, 36(2-3):291-298.
26. Qin L., Wu X., Block M.L., Liu Y., Breese G.R., Hong J.S., Knapp D.J., Crews F.T. Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia 2007, 55(5):453-462.
27. Rihmer Z., Pestality P. Bipolar II disorder and suicidal behavior. Psychiatr. Clin. North Am. 1999, 22(3). (667-673, ix-x).
28. Segal R.A., Takahashi H., McKay R.D. Changes in neurotrophin responsiveness during the development of cerebellar granule neurons. Neuron 1992, 9(6):1041-1052.
29. Soderlund J., Olsson S.K., Samuelsson M., Walther-Jallow L., Johansson C., Erhardt S., Landen M., Engberg G. Elevation of cerebrospinal fluid interleukin-1ss in bipolar disorder. J. Psychiatry Neurosci. 2010, 35(6):100080.
30. Stoll A.L., Renshaw P.F., Yurgelun-Todd D.A., Cohen B.M. Neuroimaging in bipolar disorder: what have we learned?. Biol. Psychiatry 2000, 48(6):505-517.
31. Strakowski S.M., DelBello M.P., Adler C., Cecil D.M., Sax K.W. Neuroimaging in bipolar disorder. Bipolar Disord. 2000, 2(3 Pt 1):148-164.
32. Zhang W., Qin L., Wang T., Wei S.J., Gao H.M., Liu J., Wilson B., Liu B., Kim H.C., Hong J.S. 3-hydroxymorphinan is neurotrophic to dopaminergic neurons and is also neuroprotective against LPS-induced neurotoxicity. FASEB J. 2005, 19(3):395-397.
33. Zhang W., Shin E.J., Wang T., Lee P.H., Pang H., Wie M.B., Kim W.K., Kim S.J., Huang W.H., Wang Y., Zhang W., Hong J.S., Kim H.C. 3-Hydroxymorphinan, a metabolite of dextromethorphan, protects nigrostriatal pathway against MPTP-elicited damage both in vivo and in vitro. FASEB J. 2006, 20(14):2496-2511.
34. Zhang W., Wang T., Qin L., Gao H.M., Wilson B., Ali S.F., Hong J.S., Liu B. Neuroprotective effect of dextromethorphan in the MPTP Parkinson's disease model: role of NADPH oxidase. FASEB J. 2004, 18(3):589-591.